Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

130 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Why does the lung hyperinflate?
Ferguson GT. Ferguson GT. Proc Am Thorac Soc. 2006 Apr;3(2):176-9. doi: 10.1513/pats.200508-094DO. Proc Am Thorac Soc. 2006. PMID: 16565428 Review.
Cardiovascular safety of salmeterol in COPD.
Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Ferguson GT, et al. Chest. 2003 Jun;123(6):1817-24. doi: 10.1378/chest.123.6.1817. Chest. 2003. PMID: 12796155 Clinical Trial.
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Celli BR, et al. Among authors: ferguson gt. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. doi: 10.1164/rccm.200712-1869OC. Epub 2008 May 29. Am J Respir Crit Care Med. 2008. PMID: 18511702 Clinical Trial.
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.
Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA; Investigators of the TORCH Study. Celli B, et al. Among authors: ferguson gt. Am J Respir Crit Care Med. 2011 Feb 1;183(3):317-22. doi: 10.1164/rccm.201004-0665OC. Epub 2010 Sep 2. Am J Respir Crit Care Med. 2011. PMID: 20813884 Clinical Trial.
130 results